Literature DB >> 639828

Single and multiple dose pharmacokinetics of pindolol.

R Gugler, G Bodem.   

Abstract

The pharmacokinetics of pindolol were studied in six healthy individuals following a single 10 mg dose (SD) and multiple (5 mg tid over 6 days) dose (MD). The plasma elimination half-life was identical after SD (4.7 +/- 0,8h) and MD (4.1 +/- 1.1h). Steady state plasma concentrations were reached after 36 h and remained stable thereafter. The variation in steady state concentrations was small in each individual and also between individuals. The steady state concentration of pindolol can be predicted from the pharmacokinetic data obtained after a single dose. The results of the present study suggest that the disposition of pindolol is linear over the concentration range studied.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 639828     DOI: 10.1007/BF00606675

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man.

Authors:  R Gugler; W Höbel; G Bodem; H J Dengler
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

3.  Steady-state plasma concentrations of alprenolol in man.

Authors:  M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

4.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

Review 7.  Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.

Authors:  D G Shand
Journal:  Drugs       Date:  1974       Impact factor: 9.546

8.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

View more
  10 in total

1.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

2.  Simultaneous tubular excretion and reabsorption of pindolol in man.

Authors:  L Balant; K Muir; P Dayer; A Gorgia; J L Eberlin; J Estreicher; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.

Authors:  L A Salako; A O Falase; A Ragon; R A Adio
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

Review 4.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

5.  Metabolism of pindolol in patients with renal failure.

Authors:  E E Ohnhaus; H Heidemann; J Meier; G Maurer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.

Authors:  W H Aellig; H H Narjes; E Nüesch; R J Oertle; J E Devos; W Pacha
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.

Authors:  J S Floras; J V Jones; M O Hassan; P Sleight
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-13

8.  Elimination of pindolol in liver disease.

Authors:  E E Ohnhaus; U Münch; J Meier
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain.

Authors:  Bengt Andrée; Ann Hedman; Seth-Olav Thorberg; Dag Nilsson; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

10.  Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs.

Authors:  R Gugler; R Krist; H Raczinski; K Höffgen; G Bodem
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.